Pfizer-Valneva Lyme Vaccine Nears FDA Filing as Court Injunction Freezes the Panel That Would Guide Its Rollout
核心洞察
Pfizer and Valneva (搜索) have completed a 9,000-participant Lyme vaccine (搜索) trial showing 73.2 to 74.8 percent efficacy with no safety concerns, and are preparing an FDA submission.
The vaccine missed its primary statistical goal, though Pfizer called the reduction in infections clinically meaningful; results will be presented at a scientific congress.
A March court injunction bars the 13 ACIP members appointed in 2025 from meeting or issuing new vaccine recommendations, leaving the Lyme rollout pathway undefined.
Pfizer and Valneva (搜索) are preparing to submit their Lyme disease (搜索) vaccine for U.S. Food and Drug Administration (搜索) approval after completing a trial of 9,000 participants, but the federal advisory process that would determine how the vaccine is prescribed and paid for is currently frozen by litigation — leaving the product's commercial and clinical rollout in doubt.
The vaccine, which has completed human trials, showed a 73.2 to 74.8 percent efficacy rate — the percent reduction in Lyme infection caused by the vaccine — after four doses were administered to each participant, with no safety concerns identified. The trial enrolled patients at 97 testing centers in the United States and Europe, including patients with MaineHealth and Northern Light Health. The vaccine did not meet its primary statistical goal, but Pfizer said the reduction of infections was still "clinically meaningful." A Pfizer representative said the trial results will be "presented at an upcoming scientific congress and submitted for publication in a peer-reviewed journal."
A Recommendation System in Limbo
FDA approval is only one step toward availability. Vaccines licensed by the agency are typically passed to the Centers for Disease Control and Prevention (搜索)'s Advisory Committee on Immunization Practices (搜索), whose guidance has long been considered the gold standard for vaccination and informs how physicians prescribe vaccines and which ones insurers cover.
That committee is currently unable to issue recommendations. In 2025, Health and Human Services Secretary Robert F. Kennedy Jr. fired every member of the advisory committee, and the 13 replacements he appointed drew legal backlash. A group of medical organizations filed suit in July 2025 claiming the new members had not been thoroughly vetted and lacked the credentials to provide scientific counsel. With the lawsuit ongoing, a judge ordered in March that the committee cannot meet or create recommendations about new vaccines.
According to vaccine law experts and former committee members, there is no way to know whether the Lyme vaccine (搜索) will receive the recommendations needed for an accessible rollout. A Pfizer spokesperson said it is "early to speculate" about when the vaccine might become available.
"All the rules are out the window," said Paul Offit, a physician who previously served on the advisory committee. "I don't know how this plays out."
The CDC typically forms a workgroup including advisory committee members and disease-specific experts several years before a vaccine is set to receive FDA approval, studying the disease alongside trial data and company documentation. A workgroup for Lyme was announced in April 2025, two months before Kennedy fired the entire 17-person committee on June 10. The workgroup's first presentation was scheduled for a future meeting, but after the membership changed the Lyme presentation never happened, and the disease was never added to the committee's list of active workgroups.
Charlotte Moser, a co-director of the Vaccine Education Center at Children's Hospital of Philadelphia and one of the fired members, was supposed to be part of that workgroup. "When we were fired, nobody at CDC knew that day. We all found out through the opinion piece in the Wall Street Journal," she recalled. Moser said her own application to join the committee took years of review and numerous interviews, and that when Kennedy announced a new slate within 48 hours of the firings, it was clear the new members had not undergone a similarly rigorous process.
Vaccine policy attorney Richard Hughes, on behalf of the American Academy of Pediatrics and several other medical groups, brought the July 2025 lawsuit, arguing the appointments violated the committee's charter because the members did not have the mandated expertise. The suit also contested Kennedy's January overhaul of the childhood immunization schedule. "What happened after he appointed a lot of these people is they started presenting junk science at their meetings. They started platforming misinformation. It just became a circus," Hughes said.
The March preliminary injunction halted all recommendations made by the 13 members Kennedy appointed. Kennedy subsequently announced charter updates loosening membership requirements, but the department later appealed the injunction and backpedaled the charter changes; in June he again announced loosened requirements and refocused the committee on exploring vaccine risks and non-vaccine interventions. Hughes clarified that the injunction does not prevent Kennedy from appointing qualified experts or re-appointing previous officials who could then move forward with recommendations — something the secretary has not done. Oral arguments for the appeal could begin as soon as September.
Coverage and Access at Stake
A functioning committee would instruct providers on administering an FDA-approved Lyme vaccine (搜索), particularly to at-risk populations such as children, pregnant people and those highly exposed to the disease. Its recommendation is also tied to coverage: under the Affordable Care Act, private insurers are required to cover vaccines recommended by the committee, and the Vaccines for Children Program relies on its recommendations to decide which vaccines are provided at no cost to people 18 and younger.
For seasonal vaccines such as the influenza shot, "vaccine production, coverage, and delivery is resilient enough to hold together for now" by relying in part on goodwill from insurers, according to Hughes, because providers and insurers can refer to practices with previous iterations. There is no such precedent for the new Lyme vaccine (搜索).
Independent medical groups have stepped in to fill the gap: the American Academy of Pediatrics is distributing recommendations for children, the American College of Obstetrics and Gynecologists for pregnant people, the American Academy of Family Physicians for healthy adults, and the Infectious Disease Society of America for those who are immunocompromised. But these organizations do not mandate insurance coverage the way an official committee recommendation would.
"I think there's a really heightened risk that consumers just are confused about all vaccines including this one," Hughes said, adding that incomplete insurance coverage can "cause patients not to get vaccinated." States can require vaccine coverage beyond federal requirements — Maine follows the American Academy of Pediatrics' childhood immunization schedule rather than the Trump administration's — and insurers such as Maine Community Health Options and Anthem told The Maine Monitor they consult clinical evidence and medical organization recommendations when setting coverage.
Yvonne Maldonado, a Stanford pediatrics professor and former committee member removed by Kennedy, said a patchwork approach cannot be a long-term solution. "We don't have the resources or the data to really analyze and understand the data the way the federal government does," she said, noting the committee could draw on CDC staff for additional research. Without the committee's public meetings, company trial data is also less available. "One of the victims of what's going on is transparency," said vaccine law expert Dorit Reiss. "It's a mess."
Moser said the piecemeal efforts of companies, medical organizations and states do not constitute functional public health infrastructure. "There is work that's not being done right now that should be being done when it comes to just understanding vaccines and making them available in this country," she said. "When we have chaos and confusion, there will be people who suffer outcomes that could have been prevented."
The LYMErix Precedent
Pfizer and Valneva (搜索)'s candidate would not be the first Lyme vaccine (搜索). LYMErix (搜索) was sold from 1998 to 2002 before being abruptly removed from the market due to poor sales and lawsuits from patients. Offit, who was on the committee at the time, said the short lifespan could be explained in part by an advisory committee decision to recommend that LYMErix be "considered" for patients at high risk of exposure rather than giving a full recommendation — a decision he described as politically motivated that left the manufacturer vulnerable to litigation.
Both vaccines target the same protein, and the new candidate has shown a slightly lower efficacy rate than LYMErix (搜索), meaning it appears less effective at lowering the risk of Lyme; LYMErix also required fewer doses. A Pfizer spokesperson said the company is confident in the vaccine and that one "cannot and shouldn't make comparisons to other manufacturers' vaccines." Reiss said public trust will need to be earned under the "specter" of the previous vaccine and the administration's messaging. "There's a sense that this administration — even if they approve the Lyme vaccine (搜索) and even if they come home with the recommendation — will message it in a way that will undermine uptake and undermine the vaccine in other ways," she said.
A Growing Disease Burden and a Broader Pipeline
Lyme disease (搜索) is a bacterial infection contracted through tick bites that can cause rashes, aches, stiffness, facial paralysis, fevers and an irregular heartbeat lasting for months, with residual pain and arthritis sometimes continuing for years. Nationally, nearly half a million people are treated for Lyme disease each year, and Maine has one of the highest per capita rates of infection of any state. Maine recorded its most active tickborne illness season in 2025, with providers reporting more than 4,000 Lyme cases — breaking the state's record for the third year in a row.
Diagnosis remains difficult. If a tick bite is identified within 48 hours, a standard course of antibiotics can effectively prevent disease, but people may not recognize a bite until symptoms begin days or weeks later, practitioners do not always consider testing, and tests often return false negatives. Griffin Dill, who manages a tickborne pathogen monitoring lab at the University of Maine Cooperative Extension in Orono, said warmer, shorter winters combined with housing built in ticks' forest habitat can create a "perfect storm" for exposure.
Pfizer and Valneva (搜索)'s vaccine is furthest along in the approval pipeline, but other programs are advancing: Moderna is testing two mRNA Lyme vaccines (搜索), and Tonix Pharmaceuticals (搜索) licensed a Lyme antibody (搜索) last year as part of an effort to one day provide seasonal protection, with CEO Seth Lederman seeking hospitals in Maine for an upcoming clinical trial.
Former Maine Center for Disease Control and Prevention Director Dora Mills said the state should also pursue environmental strategies to stem tick population growth, noting the Lyme vaccine (搜索) would not protect against other tickborne illnesses such as anaplasmosis (搜索), and that protective clothing, repellents and tick checks would remain important. Dill predicted a Lyme vaccine "would be relatively popular given how common tickborne illness has become in Maine." Dana Doran, executive director of the Professional Logging Contractors of the Northeast, said forest workers will want evidence they can trust the vaccine first: "They want to make sure that a product is worthy of utilization before they just go ahead and use it."